Status:
ACTIVE_NOT_RECRUITING
Association of Plasma Metabolomic Biomarkers with Chronic Ischemic White Matter Injury
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Myelinopathy
Eligibility:
All Genders
45+ years
Brief Summary
The cases were screened according to the inclusion criteria, and after the patients signed the informed consent, the clinical data were collected, the imaging data were evaluated, and blood samples we...
Detailed Description
In the early morning of the second day after the patient was enrolled, 5mL of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection o...
Eligibility Criteria
Inclusion
- Inclusion Criteria：
- Be older than 45 years old;
- Patients admitted to the Department of Neurology due to headache, vertigo, anxiety, etc.;
- There were no symptoms of neurological deficit on physical examination;
- Able to cooperate with the improvement of brain MRI examination;
- Sign the informed consent form.
- Exclusion Criteria:
- History of stroke, traumatic brain injury, intracranial tumor, central nervous system infection, active malignant tumor, thyroid disease, autoimmune disease, active or chronic inflammatory disease, severe liver and kidney impairment, etc.;
- accompanied by neurological deficit symptoms;
- refusal to participate in the study;
- Other conditions judged by the investigator to be unsuitable for enrollment.
Exclusion
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06608251
Start Date
June 1 2024
End Date
May 31 2025
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China